BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Showcases Pipeline and CEO’s Intellectual Property Legacy

Oncotelic Therapeutics (OTCQB: OTLC), a clinical stage biopharmaceutical company developing transformative oncology and immunotherapy treatments, today highlighted its oncology pipeline and the extensive intellectual property contributions of Chairman and CEO Dr. Vuong Trieu, who holds more than 500 filed and 75 issued patents and co-developed blockbuster therapeutics Abraxane(R) and Cynviloq(TM). The Company’s portfolio includes OT-101 in Phase 3 for pancreatic cancer, OXi4503 advancing toward Phase 3 in AML/MDS, CA4P/Fosbretabulin in late-stage repositioning, AL-101 in Phase 2 for Parkinson’s and sexual dysfunctions, AL-102 in discovery for Alzheimer’s, and multiple pediatric rare disease programs with potential to generate Priority Review Vouchers, reinforcing its strategy of building value through differentiated biotechnology assets with strong competitive barriers.

To view the full press release, visit https://ibn.fm/cB1OU

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The Company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates.

In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the Company also licenses and co-develops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Dr. Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics.

For more information, please visit: https://www.oncotelic.com/

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN